The Swiss pharmaceutical giant Roche has announced the launch of a new global Phase 3 clinical trial for Elevidys. This strategic move aims to generate rigorous data to support a re-submission for European approval following previous setbacks regarding the therapy’s efficacy.
Background and Rationale: Last year, the European Medicines Agency (EMA) declined to support the approval of Elevidys for ambulatory Duchenne patients. The refusal was based on previous data that failed to demonstrate a statistically significant improvement in motor function compared to a placebo. Even in the U.S., where the therapy is currently marketed, it remains controversial as the core Phase 3 trial (Embark) missed its primary endpoint of functional improvement at one year.
New Study Specifications:
-
Design: The trial will compare Elevidys against a placebo over a 72-week period, involving approximately 100 ambulatory boys.
-
Primary Endpoint: The study focuses on the change in “Time to Rise” from the floor, a critical prognostic factor for disease progression.
-
Recruitment Incentive: To encourage participation, patients initially assigned to the placebo group will be eligible to receive the actual gene therapy after the primary 72-week period.
Safety Concerns and Focus: Safety issues emerged as a major concern following two patient deaths involving severe liver injury among non-ambulatory participants. This led to label restrictions in the U.S. and prompted Roche to pause distribution in certain international territories. Consequently, Roche is currently focusing its efforts solely on the ambulatory population, where the benefit-risk profile is considered favorable and the treatment effect appears durable.